Johnson & Johnson [JNJ] Revenue clocked in at $94.88 billion, up 4.43% YTD: What’s Next?

Related

Johnson & Johnson [NYSE: JNJ] slipped around -1.82 points on Monday, while shares priced at $178.64 at the close of the session, down -1.01%. The company report on April 26, 2022 that BIOAF: Collaboration Arrangement with Janssen.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

By John Vandermosten, CFA.

Johnson & Johnson stock is now 4.43% up from its year-to-date (YTD) trading value. JNJ Stock saw the intraday high of $181.41 and lowest of $177.03 per share. The company’s 52-week high price is 186.69, which means current price is +14.72% above from all time high which was touched on 04/25/22.

Compared to the average trading volume of 8.04M shares, JNJ reached a trading volume of 6956269 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Johnson & Johnson [JNJ]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JNJ shares is $191.42 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JNJ stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Johnson & Johnson shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on April 06, 2022. While these analysts kept the previous recommendation, Bernstein raised their target price from $180 to $183. The new note on the price target was released on March 16, 2022, representing the official price target for Johnson & Johnson stock. Previously, the target price had yet another raise to $185, while BofA Securities analysts kept a Neutral rating on JNJ stock.

The Average True Range (ATR) for Johnson & Johnson is set at 3.12, with the Price to Sales ratio for JNJ stock in the period of the last 12 months amounting to 5.03. The Price to Book ratio for the last quarter was 6.35, with the Price to Cash per share for the same quarter was set at 11.82. Price to Free Cash Flow for JNJ in the course of the last twelve months was 41.30 with Quick ratio for the last quarter at 1.10.

How has JNJ stock performed recently?

Johnson & Johnson [JNJ] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.96. With this latest performance, JNJ shares gained by 0.80% in over the last four-week period, additionally plugging by 9.68% over the last 6 months – not to mention a rise of 8.13% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JNJ stock in for the last two-week period is set at 47.61, with the RSI for the last a single of trading hit 42.24, and the three-weeks RSI is set at 50.57 for Johnson & Johnson [JNJ]. The present Moving Average for the last 50 days of trading for this stock 175.18, while it was recorded at 181.87 for the last single week of trading, and 169.46 for the last 200 days.

Johnson & Johnson [JNJ]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Johnson & Johnson [JNJ] shares currently have an operating margin of +26.11 and a Gross Margin at +68.14. Johnson & Johnson’s Net Margin is presently recorded at +22.27.

Return on Equity for this stock inclined to 30.41, with Return on Assets sitting at 11.70.

Johnson & Johnson’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.

Earnings analysis for Johnson & Johnson [JNJ]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JNJ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Johnson & Johnson go to 5.47%.

Insider trade positions for Johnson & Johnson [JNJ]

There are presently around $324,379 million, or 70.20% of JNJ stock, in the hands of institutional investors. The top three institutional holders of JNJ stocks are: VANGUARD GROUP INC with ownership of 234,782,632, which is approximately 0.558% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 200,021,352 shares of the stock with an approximate value of $35.73 billion in JNJ stocks shares; and STATE STREET CORP, currently with $25.85 billion in JNJ stock with ownership of nearly 1.753% of the company’s market capitalization.

Positions in Johnson & Johnson stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,860 institutional holders increased their position in Johnson & Johnson [NYSE:JNJ] by around 51,395,466 shares. Additionally, 1,494 investors decreased positions by around 51,403,519 shares, while 345 investors held positions by with 1,713,026,012 shares. The mentioned changes placed institutional holdings at 1,815,824,997 shares, according to the latest SEC report filing. JNJ stock had 287 new institutional investments in for a total of 7,649,163 shares, while 93 institutional investors sold positions of 3,735,617 shares during the same period.